Startseite>>Myelin Basic Protein (85-99) Peptide Antagonist

Myelin Basic Protein (85-99) Peptide Antagonist

Katalog-Nr.GA23206

The antagonistic 15-peptide EKPKVEAYKAAAAPA competes with MBP (85-99), the immunodominant epitope of myelin basic protein (MBP), a major candidate autoantigen in multiple sclerosis (MS), for binding to human leukocyte antigen (HLA)-DR2. The peptide also inhibits IL-2 secretion by MBP (85-99) specific T-cell clones and induces the production of Th2 cytokines by splenocytes. Furthermore, it could be shown that the peptide is able to suppress experimental autoimmune encephalomyelitis (EAE) in several models in a manner that is equipotent to random amino acid copolymers, such as Copaxone [poly (Y,E,A,K)n]. Therefore, this synthetic peptide might be suitable in the studying of MS.

Products are for research use only. Not for human use. We do not sell to patients.

Myelin Basic Protein (85-99) Peptide Antagonist Chemische Struktur

Cas No.: 444305-16-2

Größe Preis Lagerbestand Menge
1mg
429,00 $
Auf Lager
5mg
1.717,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

The antagonistic 15-peptide EKPKVEAYKAAAAPA competes with MBP (85-99), the immunodominant epitope of myelin basic protein (MBP), a major candidate autoantigen in multiple sclerosis (MS), for binding to human leukocyte antigen (HLA)-DR2. The peptide als

Bewertungen

Review for Myelin Basic Protein (85-99) Peptide Antagonist

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Myelin Basic Protein (85-99) Peptide Antagonist

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.